Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nasal moisturizers

This article was originally published in The Tan Sheet

Executive Summary

Nasal moisturizers should be removed from FDA's OTC product review and regulated as cosmetics, law firm Kirkpatrick & Lockhart (Washington, D.C.) maintains in comments to FDA. Claims that the products provide moisture for inflamed nasal membranes due to colds "is not indicating a treatment for the cold, or other specific disease, nor is it claiming to mitigate or cure that disease," lawyers assert. The comments were submitted in response to FDA's call for data on unreviewed drug products as part of the OTC safety review (1"The Tan Sheet" Jan. 5, 2004, p. 11)...
Advertisement

Related Content

FDA Issues Call For Data On Unreviewed OTCs To Complete Drug Review
FDA Issues Call For Data On Unreviewed OTCs To Complete Drug Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS097096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel